An anti-VEGF monoclonal antibody, bevacizumab, and a multikinase inhibitor, sunitinib, upregulate Bv8 production from MDSCs, unexpectedly leading to tumor-associated angiogenesis. Here, PROK2 is linked to neoplasm.